Cm Management, LLC Lantern Pharma Inc. Transaction History

Cm Management, LLC

$97.7 Million
Q2 2025

A detailed history of Cm Management, LLC transactions in Lantern Pharma Inc. stock. As of the latest transaction made, Cm Management, LLC holds 200,000 shares of LTRN stock, worth $890,000. This represents 0.65% of its overall portfolio holdings.

Number of Shares

200,000

Previous 200,000 -0.0%

Holding current value

$890,000

Previous $708,000 10.73%

% of portfolio

0.65%

Previous 0.77%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 07, 2025	BUY	$2.9 - $4.26 $43,500 - $63,900	15,000 Added 8.11%	200,000 $636,000
Q3 2024 Nov 12, 2024	BUY	$3.42 - $4.83 $359,100 - $507,150	105,000 Added 131.25%	185,000 $678,000
Q2 2024 Aug 01, 2024	BUY	$3.91 - $9.51 $58,650 - $142,650	15,000 Added 23.08%	80,000 $373,000
Q1 2024 May 14, 2024	SELL	$3.73 - $10.65 $55,950 - $159,750	-15,000 Reduced 18.75%	65,000 $572,000
Q4 2023 Feb 12, 2024	BUY	$2.48 - $4.39 $12,400 - $21,950	5,000 Added 6.67%	80,000 $342,000
Q2 2023 Aug 04, 2023	BUY	$4.56 - $6.02 $68,400 - $90,300	15,000 Added 25.0%	75,000 $423,000
Q4 2022 Feb 09, 2023	BUY	$4.19 - $6.04 $41,900 - $60,400	10,000 Added 20.0%	60,000 $362,000
Q3 2022 Nov 04, 2022	BUY	$4.59 - $6.5 $22,491 - $31,850	4,900 Added 10.86%	50,000 $239,000
Q2 2022 Aug 08, 2022	BUY	$4.82 - $7.45 $54,634 - $84,445	11,335 Added 33.57%	45,100 $258,000
Q1 2022 May 09, 2022	BUY	$5.6 - $8.22 $189,084 - $277,548	33,765 New	33,765 $241,000
Q1 2021 May 12, 2021	SELL	$14.34 - $21.92 $143,400 - $219,200	-10,000 Closed	0 $0
Q4 2020 Feb 04, 2021	BUY	$15.1 - $20.69 $151,000 - $206,900	10,000 New	10,000 $193,000

Others Institutions Holding LTRN

# of Institutions

Shares Held

2.22M

Call Options Held

16.4K

Put Options Held

View Full List

About Lantern Pharma Inc.

Ticker LTRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 10,830,900
Market Cap $48.2M
Description
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-30...

More about LTRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cm Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cm Management, LLC with notifications on news.

Account

Cm Management, LLC Lantern Pharma Inc. Transaction History